Achieve Life Sciences/ACHV

$4.42

0%
-
1D1W1MYTD1YMAX

About Achieve Life Sciences

Achieve Life Sciences, Inc. is a late-stage clinical pharmaceutical company engaged in the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence. The Company’s product candidate, cytisinicline, is a naturally occurring, plant-based alkaloid. Cytisinicline is structurally similar to nicotine and has a well-defined, dual-acting mechanism of action that is both agonistic and antagonistic. Cytisinicline is a partial agonist that binds with high affinity to the alpha-4 beta-2, nicotinic acetylcholine receptors in the brain. Through its dual-acting partial agonist/partial antagonist activity, cytisinicline helps reduce nicotine cravings, withdrawal symptoms and reward and satisfaction associated with smoking. It is developing cytisinicline as an aid to smoking cessation and treatment for nicotine addiction to address the limitations of both prescription drugs and of over-the-counter (OTC) products.

Ticker

ACHV

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Richard Stewart

Employees

20

Headquarters

Seattle, United States

ACHV Metrics

BasicAdvanced
$151.39M
Market cap
-
P/E ratio
-$2.10
EPS
1.31
Beta
-
Dividend rate

What the Analysts think about ACHV

Analyst Ratings

Majority rating from 6 analysts.
Buy

Price Targets

Average projection from 7 analysts.
455.88% upside
High $50.00
Low $10.00
$4.42
Current price
$24.57
Average price target

ACHV Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$0
-
Net income
$-7.1M
-13.41%
Profit margin
0%
-

ACHV Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 10.19%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.83
-$0.50
-$0.43
-$0.34
-
Expected
-$0.83
-$0.69
-$0.42
-$0.38
-$0.32
Surprise
0%
-27.11%
2.03%
-10.19%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Achieve Life Sciences stock

Buy or sell Achieve Life Sciences stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing